Making the DARPin Difference Reality for Patients

Transcription

1 Making the DARPin Difference Reality for Patients Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) August 30, Molecular Partners AG Slide 1

2 Molecular Partners: Who We Are $ Teamwork Swiss biotech (SIX: MOLN) 120 team members Discovery to Phase 2 (POC) Science & patients first DARPin Therapies Abicipar in Phase 3 (ophtha) MP0250 in Phase 2 (onc) MP0274 in Phase 1 (onc) Broad preclin. I/O portfolio Partnerships Alliance with Allergan Agreement with AstraZeneca Cash CHF 122m (H1 2018) Financed well beyond key value inflection points DARPin Engine DARPin Difference: test novel therapeutic design Proof of DARPin candidates in eye and systemically Fast and cost effective drug discovery engine 2018 Molecular Partners AG Slide 2

3 Executive Management Board of Directors Experienced Management Team & Board of Directors Dr. Patrick Amstutz, CEO Co-founder, former CBO & COO Member of the Board of Directors PhD in molecular biology from UZH Bill Burns, Chairman Former CEO of Roche Pharmaceuticals Former board member of Roche, Genentech, Chugai Pharmaceuticals, Shire Dr. Andreas Harstrick, CMO, MD 30 years of experience in oncology Developed multiple mab oncology products Senior positions at Merck-Serono, Imclone, Eli Lilly Dr. Michael Stumpp, COO Göran Ando, Vice Chairman Former Chairman, Novo Nordisk Former CSO, Pharmacia Gwen Fyfe Former VP, Oncology Development at Genentech Co-founder PhD and postdoc from UZH; research in Tokyo, London Andreas Emmenegger, CFO Steven H. Holtzman President and CEO, Decibel Therapeutics Former EVP, Biogen Former CFO Glycart, Finance Roles at Roche >20 years experience as CFO of private & listed companies and in fund raising, IPOs William Bill Lee EVP Research, Gilead Dr. Pamela Trail, CSO >30 years of experience in directing cancer drug discovery at leading global pharma companies Petri Vainio Managing Director, Essex Woodlands Ventures 2018 Molecular Partners AG Slide 3

4 DARPin Proteins: Beyond Target Space of Antibodies MONOCLONAL ANTIBODIES DARPin Protein(s) Binding regions / specificity 15 kda SCALE DARPin module Binding region / specificity Opportunity to explore unique architectures to test novel therapeutic designs 150 kda Multi-DARPin product candidate High affinity and specificity Large size: 150 kda Complex architecture: 4 proteins with 12 domains Target binding via flexible surface loops (CDRs) Long half-life High affinity and specificity Small size: 15 kda (1/10 of monoclonal antibody) Simple architecture: 1 protein with 1 domain Target binding via rigid surface structure Tunable half-life 2018 Molecular Partners AG Slide 4

5 Modular Approach to Customized Drug Candidates Building blocks DARPin modules Candidates Multi-DARPin product candidate (e.g. MP0250, MP0274) Peptide linkers: Short, long, flexible, rigid High flexibility permits binding with complex geometries DARPin module conjugated to non-darpin element Non-DARPin element (chemical, toxin or other proteins) 2018 Molecular Partners AG Slide 5

6 DARPin Engine: Rapid Screening and Discovery, Flexible Design, Tailored to Therapeutic Need DARPin module selection Screening multi-darpin space of up to 10,000 functional combinations Identifying novel therapeutic designs Library of over 1 trillion DARPin proteins (modules) Combinations of up to 6+ DARPin modules, linkers Target(s) Multi-DARPin product candidate Identified DARPin modules with high target affinity Multi-DARPin product candidates 2018 Molecular Partners AG Slide 6

7 Pipeline: A Balanced and Robust Portfolio 2018 Molecular Partners AG Slide 7

8 Turning the DARPin Differentiation into Patient Outcome Our Target Profiles Preclinical Phase 1 Phase 2 Phase 3 MP0310 MP0274 MP0250 Abicipar NSCLC Wet AMD MM Tumor-restricted activity to avoid dose-limiting side effects Molecular handcuff inducing cell death in HER2+ cancer cells Blocking 2 key escape pathways in parallel Long-acting VEGF inhibitor in the eye Opening a new therapeutic window for combinations Activity in patients no longer benefiting from approved antibodies Restore activity of drugs to which cancer has become resistant in MM and NSCLC Noninferiority to competition with less frequent ocular injections 2018 Molecular Partners AG Slide 8

9 Value Ready to Capture Value Beyond Ophthalmology Oncology Value in our proprietary oncology pipeline Ophthalmology Value in ophthalmology with our partner Allergan Time Illustrative only 2018 Molecular Partners AG Slide 9

10 MP0250: A First-in-Class Multi-DARPin Product Candidate MP0250 First biologic, blocking VEGF and HGF simultaneously VEGF and HGF/c-MET key escape pathways for several SOC treatments Escape described for hematologic malignancies and solid tumors Blocking these escape pathways may restore activity of SOC drugs Our choice of indications Multiple myeloma (MM) EGFR-mutated non-small cell lung cancer (NSCLC) Potential in additional indications and combinations HGF DARPin VEGF DARPin HSA DARPin Fully owned by Molecular Partners IP protection at least until 2036 SOC, standard of care; HSA, human serum albumin Molecular Partners AG Slide 10

11 MP0250 Blocks Two Tumor Escape Pathways Untreated Upregulation of escape pathways after SOC MP0250 Medical Need: agents that block escape pathways to SOC VEGF VEGF VEGF Tumor pathways HGF (c-met) SOC HGF (c-met) HGF (c-met) HSA MP Molecular Partners AG Slide 11

12 Tumor Volume (mm 3 ) Combined HGF and VEGF Inhibition Leads to Synergistic Effect in Mouse Model Tumor Growth Inhibition Syngeneic colorectal cancer model* (MC38) MP Vehicle Anti-HGF Anti-VEGF Anti-VEGF & Anti-HGF MP Treatment (days) *Syngeneic model: HGF c-met axis fully functional murine tumor grown in mouse strain of origin Molecular Partners AG Slide 12

13 Relative Tumor Volume (%) MP0250 can be Combined with Many Agents Across Different Tumors to Increase Their Efficacy MP0250 Gastric cancer PDX model GXA3027 Head & neck cancer PDX model HNXF1905 Pancreatic cancer tumor model KP V e h ic le V e h ic le V e h ic le M P M P M P P a c lita x e l M P p a c lita x e l C is p la tin M P c is p la tin G e m c ita b in e M P g e m c ita b in e Treatment (days) PDX model, patient-derived xenograft mouse model Molecular Partners AG Slide 13

14 MP0250 in Phase 1: Safe, Convenient Dosing Clear Signs of Efficacy even on stand-alone base MP0250 Dosing* Convenient, flexible administration Exposure Repeated Favorable dosing exposure resulted in good exposure Safety Well tolerated Efficacy Clear signs of antitumor even stand-alone efficacy Infusion Well tolerated well tolerated Dosing every 2 or 3 weeks possible Systemic Half-life ~2 half-life: weeks ~2 weeks Convenient 1 hr infusion Sustained drug exposure throughout over multiple treatment cycles (up periods to 1 yr) (max. to date >12 months) Low immunogenicity Only (only 1/401 out patients of 40 developed patients with a relevant titer increase of ADAs in ADA (>10 titres) fold above background) Most common AE: was hypertension, generally well controlled with AEs as expected for standard medication: any VEGF inhibitor AEs were as expected for a VEGF inhibitor 2 Significant patients showed reduction in significant tumor volume reduction in two in tumor patients volume Treatment duration was 3 (% mo of patients): in 18 patients (40%) 3 months and 6 for mo 40% in 4 6 patients months (10%) for 10% First-in-human data strongly encourage development of DARPin therapy via systemic administration 2018 Molecular Partners AG Slide 14

15 Biological rationale Initial Indications Selected for Phase 2: MM and NSCLC multiple indications on radar Multiple myeloma MP0250 Head & neck squamous-cell EGFR-mutated NSCLC Nasopharyngeal HCC Colorectal cancer Anal cancer Feasibility of internal clinical development* Bubble size indicates estimated relative market potential (incidences). Source: Datamonitor. *Based on internal assessment on speed to market and complexity of development program. Potential of gastric, renal and other cancers under evaluation Molecular Partners AG Slide 15

16 p-c-met p-c-met Resistance in MM: up-regulation of HGF & VEGF HGF Resistance to SOC VEGF HGF score Bone Marrow MM Patients mabs 3+ 6/8 Newly diagnosed VEGF On partial remission HGF&VEGF Resistant HGF Relapsed 2+ 2/8 28% 2% 92% 89% 1+ 0/8 40% 3% 7% c-met c-met c-met c-met Moschetta M, et al. Clin Cancer Res 2013;19: ; 2. White D, et al. Cancer 2013;119: Molecular Partners AG Slide 16

17 MP0250 Unique Approach in MM Break Resistance & Restore Sensitivity mabs HGF - low Resistance to SOC induced by VEGF/HGF upregulation HGF - high MM cells reprogram the bone VEGF - low VEGF - high + MP0250 mabs MP0250 re-activates SOC activity HGF VEGF MP0250 reboots the system 2018 Molecular Partners AG Slide 17

18 MP0250 Combination with Velcade Results in Superior Efficacy in Mouse Model MP0250 Vehicle Velcade MP0250 Velcade + MP0250 Bone morphology Muscle invasion by tumor Xenograft model H Molecular Partners AG Slide 18

19 MP0250 Phase 2 Study in MM RRMM Part 1: Dose Escalation Velcade /dexamethasone Part 2: Dose Expansion MP mg/kg q3wk Velcade /dexamethasone Velcade /dexamethasone MP0250 target dose MP mg/kg q3wk Endpoints: ORR, PFS Total: n 40 MP0250 Phase 2 open-label, single-arm, multicenter study of MP Velcade + dexamethasone in patients with refractory and relapsed multiple myeloma (RRMM) Study population: MM patients who have received 2 lines of therapy, including Velcade and an IMiD, and have shown no response to most recent therapy or progressed 60 days after most recent therapy Next readouts: Additional safety and initial efficacy data before end 2018 Study details can be found at clinicaltrials.gov/nct Molecular Partners AG Slide 19

20 VGPR PR MR Baseline MP0250 Phase 2 Study in MM Initial Read-out: Promising Signs of Efficacy at initial dose (8mg/kg) MP0250 Preliminary results * : Best responses Treatment duration * (5/8 patients with anti-myeloma activity; excludes non-responders) Very good partial response Partial response Stable disease No response Patient Patient withdrew consent Patient Patient Patient progressive disease Treatment Cycle Weeks * Data cut-off: 21 May 2018; Initial dose level: 8mg/kg/3weeks Molecular Partners AG Slide 20

21 Unique Potential of MP0250 in MM MP0250 Multiple myeloma: 2 nd most common blood cancer Global market value ~USD 9.8bn, expected to reach > USD 12bn by % 25% 1 st /2 nd -line n >100,000 1 HGF/ c-met IMiD or PI + mab Transplant PI or IMiD + mab No later-line treatments target these key escape pathways 3 rd /4 th -line n 30,000 1 PI IMiD X Y + MP0250 MP0250: Potential to become backbone for all later lines 1. Including US/5EU/JP. Datamonitor Molecular Partners AG Slide 21

22 Tumor Volume (mm 3 ) HGF & VEGF Rationale in NSCLC is Supported by Preclinical & Clinical Data MP0250 Preclinical Rationale Clinical Rationale MP0250 in Lung Cancer Model HGF Rationale Activation of MET pathway appears to be significantly involved in acquired resistance to TKI Vehicle HGF/c-MET pathway is most frequently observed non-egfr related resistance mechanism to TKI Tarceva MP0250 MP Tarceva Savolitinib (c-met TKI) + osimertinib (Tagrisso ) produced 28% response in patients who failed Tagrisso and showed MET amplification; c-met amplification (15%) is a subgroup of HGF/c-MET upregulation (60 80%) 2 VEGF Rationale Treatment (days) Efficacy of VEGF (anti-angiogenesis) already clinically proven: Avastin studies 3-4 TKI, tyrosine kinase inhibitor. 1. Chabon JJ, et al. Nat Commun 2016; 2. Spigel R, et al. J Clin Onc 2017; 3. Sandler A, et al. N Engl J Med 2006; 4. Reck M, et al. J Clin Oncol Molecular Partners AG Slide 22

23 MP0250 Phase 2 Study in NSCLC MP0250 EGFR mut NSCLC after Tagrisso Part 1: Dose Escalation Tagrisso MP mg/kg q3wk Tagrisso MP mg/kg q3wk Part 2: Dose Expansion Tagrisso MP0250 target dose Endpoints: ORR, PFS Total: n 40 Status: FDA approval Sep st oncology DARPin drug candidate in US Collaboration with AstraZeneca for Tagrisso supply Next readouts: initial safety in 2018 & initial efficacy 2019 *The study details can be found on clinicaltrials.gov/nct Molecular Partners AG Slide 23

24 Unique Potential of MP0250 in EGFR mut NSCLC Current Treatment Option 1 Treatment Line Current Treatment Option 2 HGF/c-MET Iressa or Tarceva Tagrisso n Tagrisso MP0250 Tagrisso + Our Phase 2 Study NSCLC is leading cause of cancer death 1 st -line 2 nd -line n rd/ 4 th -line n Activating EGFR mutations are found in ~40% (Asia), ~20% (US), and ~15% (EU) NSCLC 2 Global market value (EGFR NSCLC) ~USD 2.8bn, expected to reach >3.5bn by 2023 (5% CAGR) 3 No targeted drug approved after patients progress under Tagrisso treatment 2018 Molecular Partners AG Slide 24 HGF/c-MET MP0250 Tagrisso + Our Phase 2 Study 1. Including actively treated, Stage IIIb and Stage IV prevalent cases in US/5EU/JP. Based on Datamonitor; 2. Tang, et al. Oncotarget 2016; 3. Datamonitor MP0250

25 MP0274: Killing HER2+ Cells with New MoA Medical need: eventually advanced cancer patients progress on standard antibody-based HER2+ treatments MP0274 is an allosteric inhibitor of HER2 blocking HER2- and HER3- mediated signaling and inducing apoptosis New mode of action: induction of apoptosis in HER2-addicted cancer cells independent of ADCC compared with approved therapies MoA may help patients not adequately responding to current therapies Ongoing Phase 1 in HER2 positive tumor patients progressing on SOC HSA DARPin HER2 DARPin B MP0274 HER2 DARPin A Fully owned by Molecular Partners IP protection until at least Molecular Partners AG Slide 25

26 MP0274 Forces Her2 in Conformational Deadlock Leading to Cell Death MP0274 Her2 EC-Domain Trastuzumab & Pertuzumab MP0274 Bi-paratopic DARPin Perjeta Herceptin Her2 has several «active sites» with conformational flexibility Herceptin and Perjeta block two distinct Her2 functions MP0274 handcuffs Her2 into fully inactive conformation*, acting as broad-range allosteric inhibitor EC: extracellular; *model 2018 Molecular Partners AG Slide 26 * model picture

27 Direct Induction of Tumor Cell Death with MP0274 «Open» MP0274 «Locked» MP0274 HER1 HER2 HER3 Apoptosis Effector-cell independent tumor cell death Natural Killer Cell HER2 signals tumor cell survival & proliferation ADCC Effector-cell mediated tumor cell death Herceptin & Perjeta ADCC, antibody-dependent cellular cytotoxicity Molecular Partners AG Slide 27

28 % Killing MP0274 is a Highly Potent Tumor Cell Killer Tumor Cell Apoptosis BT474 MP Tumor Cell Killing BT474 MP0274 Ado-trastuzumab emtansine (Kadcyla ) MP [nm] Trastuzumab/ Pertuzumab (Herceptin / Perjeta ) New MoA may help patients who do not adequately respond to current therapies [nm] 2018 Molecular Partners AG Slide 28

29 Tumor Volume (mm 3 ) Relative Tumor Volume (%) MP0274 Efficacy in PDX Mouse Models MP0274 Vehicle Trastuzumab Trastuzumab + Pertuzumab MP Breast cancer PDX model Maca4898 (Her2 IHC2+) Gastric cancer PDX model GXA3039 (Her2 IHC3/2+) Colorectal cancer PDX model CXF1991 (Her2 IHC3+) Treatment (days) Molecular Partners AG Slide 29

30 MP0274: Phase 1 Study in HER2+ Cancer Patients MP0274 Phase 1, first-in-human, single-arm, multicenter, open-label, repeated-dose, dose escalation study assess safety, tolerability and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors with expansion cohort at recommended dose to confirm safety and to assess preliminary efficacy Study treatment (estimated enrollment of 46 patients): Dose Escalation Dose Expansion at recommended dose Next readouts: Initial safety data expected in Q and first efficacy data in 2019 *Study details can be found at clinicaltrials.gov/nct Molecular Partners AG Slide 30

31 Improving the Therapeutic Index of IO Agents KILL T-Cell Engagers Immunecell ACTIVATE Costimulatory Targets BLOCK Checkpoint Targets Toxicity Efficacy Tumor Cells Tumor localized IO agents may achieve both, reduce systemic toxicity and improve efficacy 2018 Molecular Partners AG Slide 31

32 How do we achieve the improved therapeutic index? IN CIRCULATION (SYSTEMIC) IN CIRCULATION (SYSTEMIC) Clustering: activation of T-cells everywhere in body IN THE TUMOR IN THE TUMOR Activated T-cell Cell Activated T-cell Tumor Cell No Clustering = no effect Tumor Stroma Clustering: T-cell activation Stimulator SWITCH Localizer 2018 Molecular Partners AG Slide 32

33 Luminescence Signal Luminescence Signal Therapeutic Design applicable to many Agonists ,0 0 0 OX BB Link A, et al. EACR Abstr , , , , , , , , , DARPin Concentration (nm) CD OFF ON OFF Without Clustering With Clustering SWITCH 2018 Molecular Partners AG Slide 33

34 Localizer DARPin I/O Platform with Multiple Opportunities: MP0310 as the first DARPin product candidate Switch Stimulator OX BB a CD40 c A B FAP MP0310 C D Many DARPin candidates are under investigation for both solid and liquid tumors (including combinations) 2018 Molecular Partners AG Slide 34

35 MP0310: Activating T-cells (only) in the Tumor FAP: 4-1BB Tumor-restricted expression of FAP used to direct T-cell activation MP0310 Tumor-selective activation of T cells No systemic side effects expected Potential to combine with other IO SOCs (anti-pd-1, anti-ctla4) HSA DARPin FAP DARPin Fully owned by Molecular Partners IP protection at least until BB DARPin FAP, fibroblast activation protein Molecular Partners AG Slide 35

36 Animals (n) M e a n tu m o r v o lu m e [m m 3 ] CD8 T-Cells Overview of MP0310 Data MP0310 No systemic toxicity Ideally suited for combinations 10 Body weight loss >10% Vehicle TAA-CD3-AB * * * * * * Control Antibody MP0310 1/10 8/10 1/ TAA-CD3-AB + MP H u m a n C D 8 T c e lls *** * * * p e r 0.2 g tu m o r V e h ic le m g /k g a n ti-t A A /C D m g /k g a n ti-t A A /C D m g /k g a n ti-4-1 B B /F A P D A R P in m o le c u le T re a tm e n t d a y s MP0310 shows lower systemic toxicity compared with current therapy Potential combination partner for other drugs ***p<0.001, 2-way ANOVA Molecular Partners AG Slide 36

37 Retinal Diseases: Unmet Medical Needs Remain Wet AMD and DME are leading causes of blindness in Western world Large and rapidly growing group driven by aging population Current standard of care is Lucentis or Eylea Both require monthly or bi-monthly intravitreal injections Significant unmet medical need for less frequent injections and doctor office visits 2018 Molecular Partners AG Slide 37

38 Abicipar: Most Advanced DARPin Therapy, to become first and only true long-acting anti-vegf Long-acting PEGylated mono-darpin protein blocking VEGF Abicipar Potentially transformative therapy with less frequent ocular injections compared with standard of care Phase 2 data and Phase 3 topline data suggest quarterly dosing and comparable efficacy to Lucentis Allergan continues to work on further improved formulation in parallel anti-vegf DARPin Wet AMD Phase 3 one-year data presented in July 2018 Allergan plans FDA filing in H and launch in 2020 Allergan plans to start DME Phase 3 in Molecular Partners AG Slide 38

39 Phase 3 CEDAR & SEQUOIA Study Design Abicipar Source: Allergan presentation, 19 July Molecular Partners AG Slide 39

40 Primary Endpoint: STABLE VISION Abicipar Q8 and Q12 Non-Inferior to Ranibizumab Q4 With Fewer Injections Source: Allergan presentation, 19 July Molecular Partners AG Slide 40

41 Abicipar Dosed Every 8 and Every 12 Weeks Demonstrated Non-Inferiority to Ranibizumab Dosed Every 4 Weeks Source: Allergan presentation, 19 July Molecular Partners AG Slide 41

42 Economic Potential of Abicipar Collaboration Total of USD 360m in potential future milestones USD 210m development milestones pre launch Additional USD 150m sales-based milestones Tiered royalties: Low double-digit to mid-teens Attractive >USD 8 billion market, reducing the injection frequency can lead to rapid market uptake (Eylea ) Significant potential funding source to fuel growing oncology pipeline Global Wet AMD and DME Market Size (USDbn) Source: Evaluate Pharma, Accessed 27 Apr 2015; Avastin is used off label Molecular Partners AG Slide 42

43 Investment Case and Key Messages Successful transition from DARPin platform into clinical oncology company: MP0250 (Phase 2) demonstrated initial activity in MM and is progressing in NSCLC (EGFR-mut) MP0274 (Phase 1) ongoing in Her2+ cancers MP0310 selected as 1 st development candidate (preclinical) from I/O DARPin toolbox Abicipar Phase 3 in namd progressing with partner Allergan: Top-line data demonstrated non-inferiority of abicipar Q12 vs Lucentis Q4 dosing Further optimized formulation is being tested to reduce inflammation (MAPLE trial) Financed into 2020 (excluding any abicipar-related proceeds), capturing key value inflection points Keep on forward integrating towards late-stage development and the market DARPin is a registered trademark owned by Molecular Partners AG Molecular Partners AG Slide 43

44 Multiple Value Inflection Points Ahead Abicipar namd: 1-y Ph 3 efficacy Data from further optimized formulation (MAPLE trial) H1/19 FDA filing planned for H1/19 DME: Ph 3 expected start namd: expected launch MP0250 MM: initial efficacy NSCLC: initial safety MM: efficacy NSCLC: initial efficacy NSCLC: efficacy MP0274 Initial safety Initial efficacy MP0310 Preclinical data FIH Funding into 2020 (excl. any abicipar related proceeds) 2018 Molecular Partners AG Slide 44

45 Appendix 2018 Molecular Partners AG Slide 45

46 BCVA (letters ± SE) Phase 2 Data Suggest Quarterly Dosing for Wet AMD Change of Best-Corrected Visual Acuity (BCVA)* Safety Data Abicipar Abicipar 2.0 mg Abicipar 1.0 mg Vision Gain (letters) Safety (n/n) Lucentis 0.5 mg Wk 16 Wk 20 AEs / / /16 Dosing Week Allergan, 12 August *Study not powered to reach statistical significance; Ocular inflammation. SE, standard error Molecular Partners AG Slide 46

47 Financial Summary (CHF million; as per IFRS) H H change Revenues Total expenses 1 (22.1) (22.7) 0.6 Operating result EBIT (12.7) (16.7) 4.0 Net financial result 1.0 (2.7) 3.7 Net result (11.7) (19.4) 7.7 Basic net result per share (in CHF) (0.56) (0.93) 0.37 Net cash used in operations (19.4) (20.5) 1.1 Cash balance (34.5) Financial Guidance for Full-Year Total expenses at lower end of indicated CHF million range, of which around CHF 6 million non-cash effective costs Capital expenditures of ca. CHF 3 million on top No guidance on net cash flow; timelines and potential milestone payments with partnerships not disclosed Guidance subject to progress and changes in pipeline 1 Thereof non-cash costs of CHF 3.0m in H1 2018and CHF 2.6m in H Including CHF 9.8 million short-term time deposits 3 Including CHF 30.5 million short-term time deposits 4 Financial guidance as per release of H Results on August 30, Molecular Partners AG Slide 47

48 Financial Summary FY 17 (CHF million; as per IFRS) FY 2017 FY 2016 change Revenues (3.0) Total expenses 1 (45.8) (42.5) (3.3) Operating result EBIT (25.8) (19.5) (6.3) Net financial result (0.5) Net result (25.4) (18.6) (6.8) Net cash from (used in) operations (40.0) (35.4) (4.6) Cash balance (39.1) Financial Guidance for Full-Year Total expenses of ca. CHF million, of which ca. CHF 7 million non-cash effective costs Capital expenditures of ca. CHF 3 million on top No guidance on net cash flow; timelines and potential milestone payments with partnerships not disclosed Guidance subject to progress and changes in pipeline 1 Thereof non-cash costs of CHF 4.9m in FY2017 and CHF 4.7m in FY Including CHF 9.8 million short-term time deposits 3 Including CHF 30.5 million short-term time deposits 4 Financial guidance issued with FY 2017 Results release on February 08, Molecular Partners AG Slide 48

49 Shareholder Structure Shareholder structure as of June 30, 2018 Highlights VC holdings halved vs. end 2016 to 23% 23% Listed on SIX Swiss Exchange (SIX: MOLN) 59% Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech 18% 21,180,138 shares outstanding Ca. CHF 486 million market cap. as of June 30, 2018 No lock-up restrictions in place Pre-IPO investors (4 VC's) Management, Board, Founders Others Formal free float as per SIX definition: 84% 2018 Molecular Partners AG Slide 49

50 IR Agenda Date Event November 1, 2018 Q Management Statement December 6, 2018 R&D Day in New York February 7, 2019 Publication of Full-year Results 2018 (unaudited) March 15, 2019 Expected Publication of Annual Report 2018 April 16, 2019 Annual General Meeting 2018 Molecular Partners AG Slide 50

51 Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like potential, believe, assume, expect, forecast, project, may, could, might, will or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith. The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit Molecular Partners AG Slide 51

52 Molecular Partners AG Wagistrasse Zürich-Schlieren Switzerland T Molecular Partners AG Slide 52